US75886F1075
US75886F1075
Regeneron Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 14.342.900.000 | 14.202.000.000 | 1.0% |
| Cost of Revenue | 2.100.700.000 | 1.970.500.000 | 6.6% |
| Gross Profit | 12.242.200.000 | 12.231.500.000 | 0.1% |
| 8.540.200.000 | 8.240.800.000 | 3.6% | |
| Operating Income | 3.702.000.000 | 3.990.700.000 | 7.2% |
| Pretax Income | 5.230.700.000 | 4.779.900.000 | 9.4% |
| Net Income Common Stockholders | 4.504.900.000 | 4.412.600.000 | 2.1% |
| -- | -- | -- | |
| -- | -- | -- |